

Special Issue

Tumor Immunology and Immunotherapy Resistance

Message from the Guest Editors

Over the last decade, there has been an increasing understanding of molecular mechanisms that regulate anti-tumor immune responses and an exponential increase in the use of novel cancer immunotherapies in various cancer types. Despite the demonstrated success of tumor immunotherapy, most patients do not respond, and there is also a development of resistance mechanisms in patients who initially respond to immunotherapies. The scope of this Special Issue aims to cover current knowledge, cutting-edge technologies, and prospects in tumor immunology and immunotherapies. We hope that the research and review articles in this Special Issue will provide valuable references for developing next-generation cancer immunotherapies.

Dr. Timothy K. Starr

Guest Editors

Prof. Dr. Subbaya Subramanian

Dr. Timothy K. Starr

Dr. Xianda Zhao

Deadline for manuscript submissions

closed (15 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/106203

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)